Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ashley Yeo

Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.

As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.

As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.

A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.

These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”

Advertisement
Set Alert for Articles By Ashley Yeo

Latest From Ashley Yeo

Swiss Timing Is Spot-On For EU Medtech Reg Integration

Switzerland, outside the EU and the European Economic Area, has been efficient in preparing to work under the new EU medtech regulations. It’s a hoped-for model for UK stakeholders as Brexit trade talks approach.

Switzerland EU

German Industry's 'State Of The Nation' Urges Higher Profile For Medtech In 2018

Other than regulatory concerns, 2017 was a relatively problem-free year for Germany's medtech industry. But that is not expected to last far into 2018, according to the industry group BVMed, which this week laid out its priorities for the year ahead. It seems likely that a new government comprising the same coalition partners as in the previous administration will be decided early in the new year, and with it will come new health-care policy aims and budgets for 2017-2021.

Germany Policy

TxCell: Regen Med Firm's CEO Starts From Scratch

Since becoming CEO of TxCell two years ago, Stéphane Boissel has reorganized the R&D plan, restructured and reduced the head count and put the company on the road to scalable manufacturing of CAR-T regulatory cells. And he has put strategic partnerships on the agenda. It is a big change from the situation 12 months ago, he told In Vivo during the Annual European Advanced Therapies Investor Day.

Business Strategies Regenerative Medicine

Inflection Point For Regen Med Lauded At London ARM Meeting

Insights from the Alliance for Regenerative Medicine's fifth annual EU Advanced Therapies Investor Day, held in London in November 2017.

Regenerative Medicine M & A

NHS Medtech Demand-Side Should Be Greater Priority, Says UK Industry In AAR Response

The Accelerated Access Review, part of the UK's renewed push to speed access to innovations for system efficiency, cost savings and outcomes improvements, strikes most of the right notes, but there is still room for improvement in the framework of innovation adoption by the NHS, according to an industry-commissioned response to the review.

United Kingdom Market Access

UK Device Manufacturers Must Contingency Plan For A Hard Brexit

The compromise tone adopted last week by the UK government on key "phase 1" issues of an EU-UK Brexit deal was welcomed by UK health-care products industries, but with uncertainty over phase 2 – the future EU trade deal – still hampering UK business planning, local companies have no choice but to begin contingencies for a hard Brexit. Overseas stakeholders are also starting to distance themselves from a UK still unable to commit to a post-2019 relationship with the EU27.

United Kingdom Brexit
See All
Advertisement
UsernamePublicRestriction

Register